Big Data. The term is ubiquitous in our culture and its importance was validated by the attendance of over 500 people at the leadoff panel during the OCTANe 2016 Medical Device and Investor Forum. The panel, titled “Using Big Data To Improve Patient Outcomes and Reimbursement” was hosted by DevicePharm CEO, Clay Wilemon.
Every medical marketer wants to know one thing, “What are my customers thinking?”. On November 10, 2016, DevicePharm and Medical Alley will co-host an event designed to answer that very question. Titled ‘Medical Device Marketing Through the Eyes of Your Customers’, this event will feature a panel that includes surgeons, interventionalists, and hospital and practice executives from the Twin Cities area.
UK Trade & Investment — the business development arm of the British Consulate — invited DevicePharm CEO & Chief Strategy Officer, Clay Wilemon, to present to UK medical firms during a February conference.
Millions of Americans have considered weight loss surgery but made the decision that although they wanted significant weight loss, surgery was too big of a step for them. Now, with the U.S. FDA’s approval of the ReShape™ Integrated Dual Balloon System, a non-surgical weight loss procedure is available in the United States. It is called theReShape Procedure and is indicated for people with a BMI of 30 to 40.
What if you could focus your marketing plans and messaging only on the people who were actually going to buy your product or service?” This was the question posed by Clay Wilemon, DevicePharm CEO & Chief Strategy Officer, to an enthusiastic audience in San Diego during the September Device Alliance meeting.
The reality is that using predictive analytics in market research is providing a more precise way of targeting, messaging, and selling to the customers who are actually going to buy your products.
In August of 2015, the Freudenberg Group announced the formation of Freudenberg Medical. The new entity combines the resources and expertise of minimally invasive medical device specialty component, product development, and manufacturing leaders Helix Medical and MedVenture Technology under the Freudenberg Medical umbrella. By combining these two teams with the global resources of Freudenberg, medical device and pharmaceutical companies will have access to an exceptional breadth of resources in a single source relationship supported by 40,000 associates in 60 nations. The company also has manufacturing facilities in five countries including the United States, Costa Rica, Germany, Ireland, and China.
Bausch + Lomb is an iconic brand with both consumers and eye care professionals. The company launched their new Bausch + Lomb Surgical corporate campaign at the 2015 ASCRS meeting in San Diego. This campaign reflects an expanded portfolio of differentiated technologies and services for ophthalmic surgeons.
The U.S. Government states that the Affordable Care Act has three main objectives. And while these are very nice, laudable, and simple goals, they are creating paradigm shifts in the marketing and selling of medical devices.
Medical device manufacturers typically spend the greatest part of their marketing budgets hiring, training and equipping their sales team. It’s a model that makes sense in most cases, since selling a physician, hospital or GPO is critical to building market share for most device manufacturers.
But what about the consumer; does he or she really care about your medical technology brand?
There has been no shortage of press these past few years covering the world of “Big Data” and its potential impact on the strategic decision making process. According to global technology solutions provider, CSC, the world’s data growth is expected to reach thirty-five zetabytes by 2020. To put that into perspective, one-thousand megabytes equals one gigabyte. One-trillion gigabytes equals one-zetabyte. That’s a lot of data. You needn’t be a statistician to figure that out. But what exactly is big data? And what type of impact can it have on medical device marketing?